Abstracts tagged "Polymyalgia Rheumatica (PMR)"

Abstract Number: 0466 • ACR Convergence 2021
Subclinical Large Vessel Vasculitis in Polymyalgia Rheumatica
Eugenio De Miguel¹, Pierluigi Macchioni², Edoardo Conticini³, Corrado Campochiaro⁴, Rositsa Karalilova⁵, Giulia Klinowski², Paolo Falsetti³, Irene Monjo⁶, Alessandro Tomelleri⁷, Zguro Batalov⁵ and Alojzija Hocevar⁸, ¹Hospital Universitario La Paz, Madrid, Spain, ²Department of Rheumatology, IRCCS-S.Maria Nuova, Reggio Emilia, Italy, ³Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy, ⁴Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR). San Raffaele Scientific Institute, Milan. Italy, Milan, Italy, ⁵Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, ⁶Hospital La Paz - IdiPAZ, Madrid, Spain, ⁷Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR). San Raffaele Scientific Institute, Milan, Milan, Italy, ⁸UKC Ljubjana, Ljubjana, Slovenia
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are closely related diseases. PMR occurs in approximately 50 % of GCA patients1, however the frequency…
Abstract Number: 0505 • ACR Convergence 2021
Risk of Venous and Arterial Thromboembolism in Patients with Giant Cell Arteritis And/or Polymyalgia Rheumatica: A Veterans Health Administration Population-Based Study in the United States
Despina Michailidou¹, Tianyu Zhang², Pavlos Stamatis³ and Bernard Ng⁴, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Biostatistics, University of Washington, Seattle, WA, ³Lund University, Lund, Sweden, ⁴Rheumatology Section, VA Puget Sound HCS, University of Washington, Seattle, WA
Background/Purpose: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are two chronic systemic inflammatory diseases that primarily affect elderly women. Both diseases can be complicated…
Abstract Number: 0507 • ACR Convergence 2021
Tocilizumab in Patients with New Onset Polymyalgia Rheumatica (PMR-SPARE) – a Phase 2/3 Randomized Controlled Trial
Michael Bonelli¹, Helga Radner¹, Josef Smolen¹, Martina Durechova¹, Jutta Stieger², Rusmir Husic³, Andreas Kerschbaumer¹, Christian Dejaco⁴ and Daniel Aletaha⁵, ¹Medical University of Vienna, Vienna, Austria, ²2nd Department of Medicine, Hietzing Hospital, Vienna, Austria, ³Medical University of Graz, Graz, Austria, ⁴Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, Brunico, Italy, ⁵Medical University Vienna, Vienna, Austria
Background/Purpose: PMR is the second most common inflammatory rheumatic disease of people aged 50 years or older. Glucocorticoid therapy is highly effective, but many patients…
Abstract Number: 0653 • ACR Convergence 2021
Adherence to the 2015 ACR Guidelines for the Management of Polymyalgia Rheumatica and Screening for Osteoporosis at a Tertiary Care Medical Center
Padmini Parameswaran¹ and Michael Lucke², ¹Allegheny Health Network Medical Education Consortium, Pittsburgh, PA, ²Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Since the first description of polymyalgia rheumatica (PMR) in the early 1950s, the ideal dose and duration of glucocorticoid therapy has varied. In 2015,…
Abstract Number: 0952 • ACR Convergence 2021
Outcomes of COVID-19 Infection in Patients with Primary Systemic Vasculitis and Polymyalgia Rheumatica: Results from the COVID-19 Global Rheumatology Alliance Physician Registry
Sebastian Sattui¹, Richard Conway², Michael Putman³, Andrea Seet⁴, Kaley Beins⁵, Catherine Hill⁶, David Liew⁷, Sarah Mackie⁸, Puja Mehta⁹, Lorna Neill¹⁰, Gimena Gomez¹¹, Maria Salinas¹², Federico Maldonado¹³, Henrique Moriz¹⁴, Samia Studart¹⁵, NAFICE ARAUJO¹⁶, Ann Knight¹⁷, Davide Rozza¹⁸, Luca Quartuccio¹⁹, Maxime Samson²⁰, Stephane Bally²¹, Alexandre Maria²², Pascal Chazerain²³, Rebecca Hasseli²⁴, Ulf Müller-Ladner²⁵, Bimba Franziska Hoyer²⁶, Reinhard Voll²⁷, Rita Pinheiro Torres²⁸, Mariana Luis²⁹, Sandra Lúcia Ribeiro³⁰, Samar Al Emadi³¹, Jeffrey Sparks³², Tiffany Hsu³³, Kristin D'Silva³⁴, Naomi Patel³⁴, Leanna Wise³⁵, Emily Gilbert³⁶, Maria Valenzuela-Almada³⁷, Ali Duarte-Garcia³⁸, Manuel Ugarte-Gil³⁹, Emily Sirotich⁴⁰, Jean Liew⁴¹, Jonathan Hausmann⁴², Paul Sufka⁴³, Suleman Bhana⁴⁴, Rebecca Grainger⁴⁵, Wendy Costello⁴⁶, Lindsay Jacobsohn⁴⁷, Zara Izadi⁴, Anja Strangfeld⁴⁸, Elsa Frazão Mateus⁴⁹, Kimme Hyrich⁵⁰, Laure Gossec⁵¹, Loreto Carmona⁵², Saskia Lawson-Tovey⁵⁰, Lianne Kearsley-Fleet⁵³, Martin Schaefer⁵⁴, Milena Gianfrancesco⁴, Pedro Machado⁵⁵, Zachary Wallace³⁴, Jinoos Yazdany⁴ and Philip Robinson⁵⁶, ¹Hospital for Special Surgery, New York, NY, ²St. James's University Hospital, Dublin, Ireland, ³Medical College of Wisconsin, Brookfield, WI, ⁴University of California San Francisco, San Francisco, CA, ⁵Vasculitis Foundation, Kansas City, MO, ⁶Queen Elizabeth Hospital, Woodville, Australia, ⁷Austin Health, Heidelberg, Australia, ⁸School of Medicine, University of Leeds, Leeds, United Kingdom, ⁹University College London, London, United Kingdom, ¹⁰PMR GCA Scotland, Perth, United Kingdom, ¹¹Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, ¹²Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ¹³Sanatorio Güemes, Buenos Aires, Argentina, ¹⁴Hospital das Clinicas, Universidade Federal de Pernambuco, Pernambuco, Brazil, ¹⁵HOSPITAL GERAL DE FORTALEZA, Fortaleza, Brazil, ¹⁶Instituto de ASsistencia Medica ao Servidor Publico Estadual de São Paulo, São Paulo, Brazil, ¹⁷Rheumatology, Institute of Medical Sciences, Uppsala University, Uppsala, Sweden, ¹⁸Epidemiology Research Unit, Italian Society of Rheumatology, Rome, Italy, ¹⁹Clinical Rheumatology, Department of Medicine, University of Udine, Udine, Italy, ²⁰CHU Dijon Bourgogne, Hpital Franois Mitterrand, Dijon, Dijon, France, ²¹Nephrology and Dialysis Service, Metropole Savoie Hospital Center, Chambery, France, ²²Department of Internal Medicine and Multiorganic Diseases, Saint-Eloi University Hospital of Montpellier, Montpellier, France, ²³Department of Rheumatology and Internal Medicine, Diaconesses Croix Saint Simon Hospital, Paris, France, ²⁴Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus Liebig University Giessen, Bad Nauheim, Germany., Bad Nauheim, Germany, ²⁵JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol, Bad Nauheim, Germany, ²⁶Universittsklinikum Schleswig-Holstein, Kiel, Germany, ²⁷Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, ²⁸Rheumatology Service, Egas Moniz Hospital, Lisboa Occidental Hospital Centre, Lisbon, Portugal, ²⁹Department of Rheumatology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portuga, Coimbra, Portugal, ³⁰Universidade Federal do Amazonas, Amazonas, Brazil, ³¹Hamad medical corporation, Doha, Qatar, ³²Brigham and Women's Hospital, Boston, MA, ³³Brigham and Women's Hospital, Jamaica Plain, MA, ³⁴Massachusetts General Hospital, Boston, MA, ³⁵LAC+USC/Keck Medicine of USC, Pasadena, CA, ³⁶Mayo Clinic, Jacksonville, FL, ³⁷Division of Rheumatology, Mayo Clinic, Rochester, MN, ³⁸Mayo Clinic, Rochester, MN, ³⁹Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ⁴⁰McMaster University, Hamilton, ON, Canada, ⁴¹Boston University, Boston, MA, ⁴²Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ⁴³HealthPartners, Eagan, MN, ⁴⁴Crystal Run Health, Montvale, NJ, ⁴⁵University of Otago, Wellington, New Zealand, ⁴⁶Irish Children's Arthritis Network, Bansha, Ireland, ⁴⁷University of California San Francisco, Antioch, CA, ⁴⁸Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁴⁹Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, ⁵⁰University of Manchester, Manchester, United Kingdom, ⁵¹Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ⁵²Instituto de Salud Musculoesqueltica (InMusc), Madrid, Spain, ⁵³Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ⁵⁴German Rheumatism Research Center, Berlin, Germany, ⁵⁵Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁵⁶University of Queensland School of Clinical Medicine, Brisbane, Queensland, Australia, Herston, Australia
Background/Purpose: Patients with primary systemic vasculitis (PSV) and polymyalgia rheumatica (PMR) may be at high risk for poor COVID-19 outcomes due to the treatments used,…
Abstract Number: 1091 • ACR Convergence 2021
Serum Metabolomic Profiling Identifies Potential Biomarkers in Arthritis in the Elderly
Martha Cedeno¹, Jessica Murillo Saich¹, Roxana Coras², Anahy Maria Brandy-Garcia³, Agueda Prior-Español⁴, Lourdes Mateo⁵, Melania Martinez-Morillo⁵ and Monica Guma⁶, ¹University of California San Diego, La Jolla, CA, ²University of California San Diego/Department of Medicine, Autonomous University of Barcelona, San Diego, CA, ³Hospital Germans Trias i Pujol, Badalona, Spain, ⁴Department of Rheumatology, Germans Trias i Pujol. University Hospital, Badalona, Spain, ⁵Department of Rheumatology, Germans Trias i Pujol. University Hospital, Barcelona, Spain, ⁶University of California San Diego/San Diego VA Healthcare Service/Department of Medicine, Autonomous University of Barcelona, La Jolla, CA
Background/Purpose: Elderly-onset RA (EORA) and polymyalgia rheumatica (PMR) are common rheumatic diseases in the elderly, but their pathogenesis is not yet fully understood. Seronegative EORAneg…
Abstract Number: 1392 • ACR Convergence 2021
Assessment of a Patient Self-Report Frailty Tool in Patients with Polymyalgia Rheumatica
Sebastian Sattui, Deanna Jannat-Khah, Lindsay Lally, Sarah Lieber, Lisa Mandl and Robert Spiera, Hospital for Special Surgery, New York, NY
Background/Purpose: Frailty, a syndrome characterized by decreased physiologic reserve, is associated with chronic inflammation. We have shown a high prevalence of frailty in patients with…
Abstract Number: 1405 • ACR Convergence 2021
Effectiveness of Tocilizumab in Cranial and Extracranial Phenotypes of Giant Cell Arteritis: Multicenter Study of 471 Cases
Lara Sánchez-Bilbao¹, Javier Loricera¹, Santos Castañeda², Clara Moriano³, Javier Narvaez⁴, Vicente Aldasoro⁵, Olga Maíz⁶, Rafael Melero⁷, Juan Ignacio Villa⁸, Paloma Vela⁹, Susana Romero-Yuste¹⁰, José Luis Callejas¹¹, Eugenio De Miguel¹², Eva Galindez-Agirregoikoa¹³, Francisca Sivera¹⁴, Jesús Carlos Fernández-López¹⁵, Carles Galisteo¹⁶, Iván Ferraz-Amaro¹⁷, Juan Carlos Nieto¹⁸, Juan Ramón de Dios¹⁹, Julio Sánchez²⁰, Esther Fernández²¹, Isabel de la Morena²², Patricia Moya²³, Roser Solans-Laqué²⁴, Jose Luis Andreu²⁵, Marcelino Revenga²⁶, Eztizen Labrador²⁷, Andrea García-Valle²⁸, Adela Gallego²⁹, Carlota Iñíguez³⁰, Cristina Hidalgo³¹, Noemí Garrido-Puñal³², Ruth López-González³³, José Andrés Román-Ivorra³⁴, Sara Manrique Arija³⁵, Paz Collado³⁶, Enrique Raya¹¹, Francisco Navarro³⁷, Antoni Juan Mas³⁸, Carmen Ordas³⁹, Maria Dolors Boquet⁴⁰, Noelia Álvarez-Rivas⁴¹, Maria Luisa Velloso-Feijoo⁴², Cristina Campos-Fernández⁴³, Íñigo Rúa-Figueroa⁴⁴, Arantxa Conesa⁴⁵, Eva Salgado⁴⁶, Miguel Ángel gonzalez-Gay⁴⁷ and Ricardo Blanco⁴⁸, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario de la Princesa, Madrid, Spain, ³Hospital Universitario de León, León, Spain, ⁴Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁵Complejo Hospitalario de Navarra, Pamplona, Spain, ⁶Hospital Universitario de Donostia, San Sebastián, Spain, ⁷Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ⁸Hospital Sierrallana, Torrelavega, Spain, ⁹Hospital General Universitario de Alicante, Alicante, Spain, ¹⁰Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ¹¹Hospital San Cecilio, Granada, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³Hospital Universitario de Basurto, Bilbao, Spain, ¹⁴Hospital Universitario de Elda, Alicante, Spain, ¹⁵Hospital Universitario Juan Canalejo, A Coruña, Spain, ¹⁶Hospital Universitari Parc Tauli, Saadell, Spain, ¹⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁸Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹⁹Hospital Universitario de Araba, Mondragón, Spain, ²⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ²¹Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ²²Hospital Clínico Universitario de Valencia, Valencia, Spain, ²³Hospital Sant Pau, Barcelona, Spain, ²⁴Hospital Vall d'Hebron, Barcelona, Spain, ²⁵Hospital Universitario Puerta de Hierro, Madrid, Spain, ²⁶Hospital Universitario Ramón y Cajal, Madrid, Spain, ²⁷Hospital San Pedro, Logroño, La Rioja, Spain, ²⁸Complejo Asistencial Universitario de Palencia, Palencia. Spain, Palencia, Spain, ²⁹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ³⁰Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain, ³¹Hospital Universitario Salamanca, Salamanca, Spain, ³²Hospital Universitario Virgen del Rocío, Sevilla, Spain, ³³Complejo Hospitalario de Zamora, Zamora, Spain, ³⁴Hospital Universitario y Politécnico La Fe, Valencia, Spain, ³⁵Hospital Regional de Málaga, Málaga. Spain., Malaga, Spain, ³⁶Hospital Universitario Severo Ochoa, Madrid, Spain, ³⁷Hospital General Universitario de Elche, Elche, Spain, ³⁸Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ³⁹Hospital de Cabueñes, Gijón, Spain, ⁴⁰Hospital Arnau de Vilanova, Lleida. Spain., Lleida, Spain, ⁴¹Hospital San Agustín, Aviles, Spain, ⁴²Hospital Universitario de Valme, Sevilla, Spain, ⁴³Consorci Hospital General Universitari de Valencia, Valencia, Spain, ⁴⁴Hospital Universitario Doctor Negrín, Gran Canaria, Spain, ⁴⁵Hospital Universitario de Castellón, Castellón, Spain, ⁴⁶Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ⁴⁷Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Giant cell arteritis (GCA) may be divided into cranial, and extracranial GCA phenotypes. Tocilizumab (TCZ) has shown efficacy and safety in GCA.Our aim was…
Abstract Number: 1407 • ACR Convergence 2021
Characterization of Synovial Fluid T Cells in Polymyalgia Rheumatica: Implication of Th1 and Tc1 Effector Memory Profiles
Rosanne Reitsema¹, Lieske Wekema², Wayel Abdulahad¹, Peter Heeringa³, Minke Huitema¹, Maria Sandovici³, Annemieke Boots³, Elisabeth Brouwer³ and Kornelis van der Geest³, ¹Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Polymyalgia Rheumatica (PMR) is a common rheumatic inflammatory disease in the elderly. PMR is characterized by synovial inflammation of (peri)articular structures in the shoulders…
Abstract Number: 1416 • ACR Convergence 2021
Dysregulated Glucose Metabolism and Dyslipidemia in GCA and PMR Patients at Diagnosis
Idil Esen¹, Philip Therkildsen², Berit Dalsgaard Nielsen², Anna van 't Ende¹, Annemieke Boots¹, Peter Heeringa¹, Ellen-Margrethe Hauge², Elisabeth Brouwer¹ and Yannick van Sleen³, ¹University Medical Center Groningen, Groningen, Netherlands, ²Aarhus University Hospital, Aarhus, Denmark, ³University of Groningen, Groningen, Netherlands
Background/Purpose: Giant cell arteritis (GCA) is the large and medium vasculitis that affects elderly people GCA frequently overlaps with polymyalgia rheumatica (PMR). PMR is a…
Abstract Number: 1418 • ACR Convergence 2021
Patient Reported Outcomes on Quality of Life in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
Yannick van Sleen¹, Kornelis van der Geest², Annemieke Boots², Maria Sandovici² and Elisabeth Brouwer², ¹University of Groningen, Groningen, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are often overlapping inflammatory diseases that occur in people older than 50 years. Both diseases can…
Abstract Number: 0794 • ACR Convergence 2020
Peripheral Blood T and B Lymphocyte Subsets in Arthritis in the Elderly
Aina Teniente-Serra¹, Lourdes Mateo², Agueda Prior³, Monica Guma⁴, Eva Martinez-Caceres¹ and Melania Martinez-Morillo⁵, ¹Department of Immunology, Germans Trias i Pujol. University Hospital, Badalona, Badalona, ²Department of Rheumatology, Germans Trias i Pujol. University Hospital, Badalona, Badalona, ³Department of Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ⁴Division of Rheumatology, University of California San Diego, Department of Medicine, Autonomous University of Barcelona, La Jolla, CA, ⁵Hospital Germans Trias i Pujol, Barcelona, Spain
Background/Purpose: Multiple lymphocyte subsets like T and B cells have been connected to joint infiltration and inflammation in rheumatoid arthritis (RA). Identification of leucocyte subsets…
Abstract Number: 1580 • ACR Convergence 2020
Generalized Immune Activation in Structures Related to PMR or GCA on PET/CT Assessment Does Not Occur in Immune Checkpoint Inhibitor-Treated Patients Who Do Not Go on to Develop Rheumatic Immune-Related Adverse Events
David Liew¹, Aurora Poon², Christopher McMaster³, Claire Owen⁴, Jessica Leung⁵, Albert Frauman², Jonathan Cebon⁶, Andrew Scott⁶ and Russell Buchanan⁷, ¹Austin Health, Melbourne, Victoria, Australia, Heidelberg, Victoria, Australia, ²Austin Health, Melbourne, Victoria, Australia, Melbourne, Victoria, Australia, ³Austin Health, Melbourne, Victoria, Australia, Pascoe Vale South, Victoria, Australia, ⁴Austin Health, Melbourne, Victoria, Australia, Ashburton, Victoria, Australia, ⁵Austin Health, Melbourne, Victoria, Australia, Melbourne, ⁶Austin Health, Melbourne, Victoria, Australia, Melbourne, Australia, ⁷Austin Health, Melbourne, Victoria, Australia, Heidelberg, Melbourne, Victoria, Australia
Background/Purpose: The pathogenesis of rheumatic immune-related adverse events (irAEs) from checkpoint inhibitor cancer immunotherapy directed against programmed cell death protein 1 (PD-1) and programmed death…
Abstract Number: 1934 • ACR Convergence 2020
What Is the Significance of Periarterial Temporal Small Vessel Inflammation (SVI) on Temporal Artery Biopsy (TAB) in the Diagnosis of Vasculitis? A Systematic Review and Meta-analysis
Elise Belilos¹, Steven Carsons² and Sonya Mehta¹, ¹NYU Winthrop Hospital, Mineola, NY, ²NYU Long Island School of Medicine, Mineola, NY
Background/Purpose: Isolated inflammation of small vessels including capillaries, venules and arterioles surrounding a normal temporal artery (SVI) in patients suspected of having giant cell arteritis…
Abstract Number: 0131 • ACR Convergence 2020
Analysis of the Total Body Composition in a Cohort of Patients with Elderly Onset Arthritis
Anahy María Brandy García¹, Melania Martinez-Morillo², Agueda Prior³, Rosa Serrano¹, Lourdes Mateo⁴, Monica Guma⁵ and Laia Gifre², ¹Hospital Germans Trias i Pujol, Badalona, Spain, ²Hospital Germans Trias i Pujol, Barcelona, Spain, ³Department of Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ⁴Department of Rheumatology, Germans Trias i Pujol. University Hospital, Badalona, Badalona, ⁵University of California San Diego, La Jolla, CA
Background/Purpose: Inflammatory arthritis in the elderly leads to greater comorbidity than that of the young patients, however, there are few data on body composition in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].